| Literature DB >> 21811910 |
Matthew Grant1, Rafik Samuel, Robert L Bettiker, Byungse Suh.
Abstract
Over the past four years, significant advances have been made in human immunodeficiency virus (HIV) therapy. In addition to the release of two new classes of antiretrovirals, our understanding of the older antiretrovirals continues to improve. Multiple combination pills have been brought to market, simplifying the regimens for patient ease. New controversies have arisen, notably the role of antiretrovirals in the chronic inflammatory state that HIV infection produces, which may lead to excess cardiac, renal, and hepatic mortality. The optimum time to initiate antiretroviral therapy remains unknown but clinicians are treating HIV infection earlier in its course. In this article, we review these and other new issues relating to the care of the HIV patient.Entities:
Mesh:
Substances:
Year: 2011 PMID: 21811910 DOI: 10.1007/s12272-011-0701-3
Source DB: PubMed Journal: Arch Pharm Res ISSN: 0253-6269 Impact factor: 4.946